MX2012005275A - Composiciones y metodos para tratar colitis. - Google Patents

Composiciones y metodos para tratar colitis.

Info

Publication number
MX2012005275A
MX2012005275A MX2012005275A MX2012005275A MX2012005275A MX 2012005275 A MX2012005275 A MX 2012005275A MX 2012005275 A MX2012005275 A MX 2012005275A MX 2012005275 A MX2012005275 A MX 2012005275A MX 2012005275 A MX2012005275 A MX 2012005275A
Authority
MX
Mexico
Prior art keywords
substituted
unsubstituted
methyl
hydroxy
salt
Prior art date
Application number
MX2012005275A
Other languages
English (en)
Spanish (es)
Inventor
Robert Shalwitz
Joseph H Gardner
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of MX2012005275A publication Critical patent/MX2012005275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2012005275A 2009-11-06 2010-11-05 Composiciones y metodos para tratar colitis. MX2012005275A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25891809P 2009-11-06 2009-11-06
US25891409P 2009-11-06 2009-11-06
PCT/US2010/055704 WO2011057121A1 (en) 2009-11-06 2010-11-05 Compositions and methods for treating colitis

Publications (1)

Publication Number Publication Date
MX2012005275A true MX2012005275A (es) 2012-06-19

Family

ID=43970365

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2012005274A MX2012005274A (es) 2009-11-06 2010-11-05 Inhibidores de prolil hidroxilasa.
MX2012005273A MX2012005273A (es) 2009-11-06 2010-11-05 Metodos para incrementar la estabilizacion de factor-1 alfa inducible por hipoxia.
MX2012005275A MX2012005275A (es) 2009-11-06 2010-11-05 Composiciones y metodos para tratar colitis.
MX2013009454A MX365138B (es) 2009-11-06 2010-11-05 Inhibidores de prolil hidroxilasa.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012005274A MX2012005274A (es) 2009-11-06 2010-11-05 Inhibidores de prolil hidroxilasa.
MX2012005273A MX2012005273A (es) 2009-11-06 2010-11-05 Metodos para incrementar la estabilizacion de factor-1 alfa inducible por hipoxia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013009454A MX365138B (es) 2009-11-06 2010-11-05 Inhibidores de prolil hidroxilasa.

Country Status (28)

Country Link
US (11) US8309537B2 (OSRAM)
EP (9) EP2952192B1 (OSRAM)
JP (6) JP5627040B2 (OSRAM)
KR (8) KR101591701B1 (OSRAM)
CN (3) CN102638983B (OSRAM)
AU (3) AU2010314982B2 (OSRAM)
BR (3) BR112012010762B1 (OSRAM)
CA (3) CA2774043C (OSRAM)
DK (4) DK2649998T3 (OSRAM)
ES (5) ES2533128T3 (OSRAM)
HK (1) HK1208806A1 (OSRAM)
HR (3) HRP20150772T1 (OSRAM)
HU (1) HUE026109T2 (OSRAM)
IL (4) IL219610A (OSRAM)
IN (3) IN2012DN04949A (OSRAM)
MX (4) MX2012005274A (OSRAM)
MY (3) MY163511A (OSRAM)
NO (1) NO2853265T3 (OSRAM)
NZ (4) NZ600396A (OSRAM)
PH (3) PH12012500790A1 (OSRAM)
PL (4) PL2649998T3 (OSRAM)
PT (4) PT2853265T (OSRAM)
RS (3) RS52870B (OSRAM)
RU (3) RU2518416C2 (OSRAM)
SI (2) SI2496084T1 (OSRAM)
SM (1) SMT201300096B (OSRAM)
WO (3) WO2011057115A1 (OSRAM)
ZA (1) ZA201204104B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US9205129B2 (en) * 2009-10-09 2015-12-08 University Of Rochester Methods of treatment and screening assays for HIF-1α regulation
EP2952192B1 (en) * 2009-11-06 2019-05-15 Aerpio Therapeutics, Inc. Prolyl hydroxylase inhibitors
CN103717214A (zh) * 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
NO2686520T3 (OSRAM) 2011-06-06 2018-03-17
BR112014008819A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Métodos para o tratamento de síndrome de vazamento vascular e câncer
DK2967049T3 (da) * 2013-03-15 2020-12-07 Univ Southern California Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
SG11201507131WA (en) 2013-03-15 2015-10-29 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CA2914662C (en) 2013-06-13 2022-05-31 Robert Shalwitz Compositions and methods for treating anemia
SG11201606862VA (en) * 2014-02-19 2016-09-29 Aerpio Therapeutics Inc Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
TW201632504A (zh) 2015-01-23 2016-09-16 阿克比治療有限公司 ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
CN112088155A (zh) 2018-05-09 2020-12-15 阿克比治疗有限公司 用于制备2-[[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基]乙酸的方法
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
US20220401423A1 (en) * 2019-11-20 2022-12-22 Angion Biomedica Corp. Methods for treating inflammatory bowel disease
WO2021119033A1 (en) 2019-12-09 2021-06-17 Gb004, Inc. Compositions and methods of treatment
WO2021182490A1 (ja) * 2020-03-11 2021-09-16 キッセイ薬品工業株式会社 イミダゾピリジノン化合物又はその塩の結晶
WO2022036269A1 (en) * 2020-08-13 2022-02-17 Gb004, Inc. CRYSTALLINE FORMS OF AN HIF-1α PROLYL HYDROXYLASE INHIBITOR
WO2022036267A1 (en) 2020-08-13 2022-02-17 Gb004, Inc. Compositions and methods of treatment
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
EP4288427A1 (en) * 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
KR102507532B1 (ko) * 2022-09-14 2023-03-10 주식회사 에이치디에스바이오 락토바실러스 플란타룸 hac03 균주 및 플라보노이드를 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2024165507A1 (en) * 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Use of hif-1α stabilizing agents for the treatment of type i interferonopathies
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US3853900A (en) 1973-09-14 1974-12-10 Searle & Co 4-benzyloxy-2 (1h)-pyridones
US5358949A (en) 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
TW219933B (OSRAM) 1990-02-26 1994-02-01 Lilly Co Eli
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
DE4316077A1 (de) 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
DK0650960T3 (da) * 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US6046219A (en) 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
KR20000065090A (ko) 1996-04-30 2000-11-06 훽스트 악티엔게젤샤프트 3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
EP1357111B1 (en) 2000-12-28 2009-08-05 Shionogi & Co., Ltd. 2-pyridone derivatives having affinity for cannabinoid type 2 receptor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
US20030153503A1 (en) * 2001-12-06 2003-08-14 Klaus Stephen J. Methods of increasing endogenous erythropoietin (EPO)
CA2472576C (fr) 2002-01-11 2009-06-23 Rhodianyl Utilisation du sulfure de zinc comme agent antiacarien
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
MXPA05009771A (es) * 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
SI1644336T1 (sl) 2003-06-06 2011-06-30 Fibrogen Inc Heteroarilne spojine, ki vsebujejo duĺ ik in njihova uporaba pri zviĺ anju endogenega eritropoetina
WO2005023328A2 (en) * 2003-08-26 2005-03-17 Becton Dickinson And Company Methods for intradermal delivery of therapeutics agents
AU2004285351A1 (en) * 2003-10-31 2005-05-12 Earth Chemical Co., Ltd. Material in gel state
WO2005051933A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
US20070155744A1 (en) 2004-01-30 2007-07-05 Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors
US20050258126A1 (en) 2004-05-21 2005-11-24 Aniceto Canamasas Puigbo Double bottomed jar
ATE443775T1 (de) 2004-05-28 2009-10-15 Fibrogen Inc Hif-prolylhydroxylase-aktivitätstest
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
US7588824B2 (en) * 2005-02-25 2009-09-15 The Regents Of The University Of California Hydrogen cyano fullerene containing proton conducting membranes
WO2006105670A1 (en) * 2005-04-08 2006-10-12 Neuromed Pharmaceuticals Ltd. Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
US8177417B2 (en) * 2005-04-25 2012-05-15 Harsco Technologies Corporation Apparatus for continuous blending
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
ES2446416T3 (es) 2005-12-09 2014-03-07 Amgen, Inc. Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
WO2007123777A2 (en) 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PT3357911T (pt) * 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
JP5265381B2 (ja) 2006-12-07 2013-08-14 テルモ株式会社 輸液チューブセット
CA2672656C (en) 2006-12-18 2012-03-20 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
US20100056563A1 (en) 2007-04-18 2010-03-04 Deodialsingh Guiadeen Novel 1.8-naphthyridine compounds
AU2008248234B2 (en) 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CN101678011B (zh) 2007-05-16 2012-07-18 默沙东公司 螺氮茚酮化合物
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
EP2188295A4 (en) 2007-08-10 2011-11-16 Crystalgenomics Inc PYRIDINE DERIVATIVES AND METHODS OF USE
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
FR2924205B1 (fr) 2007-11-23 2013-08-16 Air Liquide Dispositif et procede de refrigeration cryogenique
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
EP2227770A4 (en) 2007-11-30 2011-11-09 Glaxosmithkline Llc PROLYLHYDROXYLASEINHIBITOREN
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009076343A2 (en) 2007-12-13 2009-06-18 Archer-Daniels-Midland Company Alcoholic xylose fermentation at high temperatures by the thermotolerant yeast hansenula polymorpha
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
PT2385763T (pt) 2009-01-12 2018-07-13 Aerpio Therapeutics Inc Métodos para tratar o síndrome de extravasamento vascular
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP2952192B1 (en) 2009-11-06 2019-05-15 Aerpio Therapeutics, Inc. Prolyl hydroxylase inhibitors
PH12013500577B1 (en) 2010-10-07 2019-06-28 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
BR112014008819A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Métodos para o tratamento de síndrome de vazamento vascular e câncer
CN104066448A (zh) 2011-10-13 2014-09-24 阿尔皮奥治疗学股份有限公司 眼病的治疗
SG11201507131WA (en) 2013-03-15 2015-10-29 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
SG11201606862VA (en) 2014-02-19 2016-09-29 Aerpio Therapeutics Inc Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
US9757124B2 (en) 2014-02-24 2017-09-12 Ethicon Llc Implantable layer assemblies

Also Published As

Publication number Publication date
KR20120079846A (ko) 2012-07-13
US20110112055A1 (en) 2011-05-12
JP2013508462A (ja) 2013-03-07
MX2012005274A (es) 2012-06-19
HRP20150473T1 (hr) 2015-06-05
CA2774043A1 (en) 2011-05-12
ES2424122T3 (es) 2013-09-27
ES2644998T3 (es) 2017-12-01
PL2496084T3 (pl) 2015-09-30
KR20150116464A (ko) 2015-10-15
PH12012500788A1 (en) 2016-07-27
PT2496236E (pt) 2013-07-08
US8999971B2 (en) 2015-04-07
IL219611A0 (en) 2012-07-31
AU2010314973B9 (en) 2015-03-19
EP2496082B1 (en) 2016-10-12
CN102612367A (zh) 2012-07-25
JP5591939B2 (ja) 2014-09-17
HK1208806A1 (en) 2016-03-18
RS52870B (sr) 2013-12-31
NO2853265T3 (OSRAM) 2017-12-23
WO2011057115A1 (en) 2011-05-12
CN102595896B (zh) 2016-02-17
ES2782999T3 (es) 2020-09-16
EP2496084B1 (en) 2015-06-10
EP2496084A4 (en) 2012-11-21
MY160066A (en) 2017-02-15
AU2010314982B2 (en) 2013-08-29
PT2649998E (pt) 2015-04-21
CN102612367B (zh) 2014-02-19
US20140364419A1 (en) 2014-12-11
NZ600396A (en) 2014-08-29
EP2649998A1 (en) 2013-10-16
US20220185778A1 (en) 2022-06-16
HRP20130691T1 (en) 2013-10-11
JP5627040B2 (ja) 2014-11-19
KR20140122283A (ko) 2014-10-17
JP2014221826A (ja) 2014-11-27
HRP20150772T1 (hr) 2015-08-28
US9540326B2 (en) 2017-01-10
IN2012DN04949A (OSRAM) 2015-09-25
EP3698794A1 (en) 2020-08-26
US8778412B2 (en) 2014-07-15
KR101445946B1 (ko) 2014-09-29
AU2010314973A1 (en) 2012-06-21
RU2518071C2 (ru) 2014-06-10
BR112012010762B1 (pt) 2021-08-03
IL219610A (en) 2015-07-30
US20110110961A1 (en) 2011-05-12
JP2013508464A (ja) 2013-03-07
JP2013508463A (ja) 2013-03-07
HK1169275A1 (en) 2013-01-25
PH12012500790A1 (en) 2012-11-26
EP2853265A1 (en) 2015-04-01
AU2010314982A1 (en) 2012-06-21
US20170298019A1 (en) 2017-10-19
CA2774046E (en) 2011-05-12
KR101613103B1 (ko) 2016-04-18
KR20140048341A (ko) 2014-04-23
ES2541613T3 (es) 2015-07-22
CN102638983A (zh) 2012-08-15
DK2496084T3 (en) 2015-06-29
EP2496082A1 (en) 2012-09-12
MY163511A (en) 2017-09-15
SI2649998T1 (sl) 2015-06-30
EP2496236A1 (en) 2012-09-12
ZA201204104B (en) 2013-02-27
KR20150016414A (ko) 2015-02-11
JP5961665B2 (ja) 2016-08-02
PL2649998T3 (pl) 2015-08-31
PL2496236T4 (pl) 2015-11-30
PL2496236T3 (pl) 2013-10-31
PL2853265T3 (pl) 2018-01-31
DK2649998T3 (en) 2015-05-04
CA2774043C (en) 2015-04-14
MX2012005273A (es) 2012-06-19
NZ629733A (en) 2016-02-26
EP2952192A1 (en) 2015-12-09
BR112012010766A2 (pt) 2015-10-06
CA2774039A1 (en) 2011-05-12
HK1169313A1 (en) 2013-01-25
EP2496236B1 (en) 2013-05-01
US20110111058A1 (en) 2011-05-12
RS54124B1 (sr) 2015-12-31
US20130158045A1 (en) 2013-06-20
US9045495B2 (en) 2015-06-02
EP2496082A4 (en) 2012-11-21
AU2010314976B2 (en) 2014-03-06
EP2853265B1 (en) 2017-07-26
KR101591701B1 (ko) 2016-02-05
KR20120079844A (ko) 2012-07-13
CA2774046C (en) 2014-01-21
WO2011057112A1 (en) 2011-05-12
BR112012010759A2 (pt) 2015-10-06
DK2496236T3 (da) 2013-07-08
US8536181B2 (en) 2013-09-17
SMT201300096B (it) 2013-11-08
CN102638983B (zh) 2014-11-26
RU2521251C2 (ru) 2014-06-27
EP2649998B1 (en) 2015-03-04
NZ600405A (en) 2014-08-29
JP2014159427A (ja) 2014-09-04
KR101483831B1 (ko) 2015-01-21
PT2496084E (pt) 2015-08-21
IL219611A (en) 2017-03-30
IL239918A0 (en) 2015-08-31
KR20140095105A (ko) 2014-07-31
EP2954899A1 (en) 2015-12-16
IL219612A (en) 2016-11-30
RU2012123386A (ru) 2013-12-20
JP2014139206A (ja) 2014-07-31
EP2496236A4 (en) 2012-09-12
EP2496084A1 (en) 2012-09-12
AU2010314973B2 (en) 2014-08-28
EP2954899B1 (en) 2020-01-08
JP5865411B2 (ja) 2016-02-17
EP2952192B1 (en) 2019-05-15
JP5599467B2 (ja) 2014-10-01
ES2533128T3 (es) 2015-04-07
NZ600400A (en) 2014-09-26
RU2012123388A (ru) 2013-12-20
HUE026109T2 (en) 2016-05-30
US10562854B2 (en) 2020-02-18
KR20120088833A (ko) 2012-08-08
US20150218098A1 (en) 2015-08-06
RS54010B1 (sr) 2015-10-30
WO2011057121A1 (en) 2011-05-12
MX365138B (es) 2019-05-24
PT2853265T (pt) 2017-11-07
IL219610A0 (en) 2012-07-31
US8883774B2 (en) 2014-11-11
CA2774046A1 (en) 2011-05-12
BR112012010762A2 (pt) 2018-03-20
US20150157617A1 (en) 2015-06-11
AU2010314976A1 (en) 2012-06-21
DK2853265T3 (da) 2017-11-06
US8309537B2 (en) 2012-11-13
RU2012123387A (ru) 2013-12-20
EP3603644A1 (en) 2020-02-05
SI2496084T1 (sl) 2015-08-31
US20130158010A1 (en) 2013-06-20
IN2012DN04940A (OSRAM) 2015-09-25
CN102595896A (zh) 2012-07-18
US20190055198A1 (en) 2019-02-21
US9278930B2 (en) 2016-03-08
RU2518416C2 (ru) 2014-06-10
IN2012DN04950A (OSRAM) 2015-09-25
IL219612A0 (en) 2012-07-31
BR112012010759B1 (pt) 2021-12-28
MY161880A (en) 2017-05-15
PH12012500789A1 (en) 2012-11-26
HK1190334A1 (en) 2014-07-04

Similar Documents

Publication Publication Date Title
DK2496084T3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF colitis
HK40033628A (en) Compositions and methods for treating colitis
HK1169275B (en) Compositions and methods for treating colitis
HK1190334B (en) Prolyl hydroxylase inhibitors
HK1169274B (en) Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
HK1169313B (en) Prolyl hydroxylase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration